Business Context and Reporting Period
This Form 8-K filing by Sunshine Heart, Inc. (not Nuwellis, Inc.) reports material definitive agreements entered into on October 30, 2016. The company, a biotechnology firm, executed a Securities Exchange Agreement to restructure existing Series B Preferred Stock and a Securities Purchase Agreement to raise capital through a Registered Direct Offering and a Private Placement.
Key Financial Metrics and Capital Structure
- Expected Proceeds: The company expects to receive approximately $3.3 million at the Initial Closing (expected November 3, 2016) and $0.2 million at the Second Closing, totaling approximately $3.5 million in net proceeds.
- Use of Proceeds: Funds are designated for working capital needs related to the recently acquired Aquadex product line and general corporate purposes.
- Securities Issued:
- Series B-1 Preferred Stock: 2,227.2 shares issued in exchange for Series B Preferred Stock.
- Series C Preferred Stock: 2,900 shares sold at $0.17 per share.
- Series D Preferred Stock: 900 shares sold at $0.17 per share (700 at Initial Closing, 200 at Second Closing).
- Warrants: 22,352,941 warrants issued to purchase common stock at an exercise price of $0.18 per share.
- Placement Agent Fees: Northland Securities, Inc. received a 6% cash fee on gross proceeds and warrants equal to 6% of the common shares sold or issuable upon conversion.
Material Changes and Agreements
The filing details a significant restructuring of the company's capitalization table:
- Preferred Stock Exchange: Existing Series B Preferred Stock was exchanged for Series B-1 Preferred Stock with an initial conversion price of $0.17 per share. Conversion is limited until shareholder approval is obtained to comply with Nasdaq Listing Rule 5635(d).
- Two-Stage Closing: The capital raise is split into an Initial Closing (subject to customary conditions) and a Second Closing (subject to shareholder approval).
- Shareholder Approval Requirement: A special meeting of shareholders must be held within 120 days of the Initial Closing to approve the issuance of common stock underlying the new preferred stock and warrants. No common stock is issuable upon conversion or exercise until this approval is received.
Outlook, Risks, and Contingencies
- Conversion Terms: Both Series C and Series D Preferred Stock have a conversion price of $0.17, subject to anti-dilution adjustments if the company issues equity at a lower price. Series D includes a "ratchet" provision reducing the conversion price to 80% of the VWAP after six months or following a reverse stock split.
- Redemption Rights: The company may redeem Series D Preferred Stock for cash at a premium (120% to 150% of stated value) depending on the timing relative to the issuance date. Holders also have redemption rights upon certain triggering events.
- Liquidated Damages: The company faces significant penalties for failing to timely deliver shares upon conversion, starting at $50 per business day per $5,000 of stated value and increasing to $200 per business day.
- Forward-Looking Risks: Management notes risks regarding regulatory approvals, clinical trial outcomes, and the possibility that shareholders may not approve the offering, which would prevent the Second Closing and conversion of securities.
Investor Verification Checklist
- Verify the outcome of the shareholder vote required for the Second Closing and conversion of Series C and D Preferred Stock.
- Confirm the actual closing date and final net proceeds received, as these are subject to customary closing conditions.
- Monitor the company's cash burn rate to assess if the $3.5 million in proceeds is sufficient to fund the Aquadex product line and operations until the next financing.
- Review the specific terms of the "Triggering Redemption Amount" for Series D Preferred Stock to understand potential future cash outflows.
- Check for any subsequent equity issuances that might trigger anti-dilution adjustments to the $0.17 conversion price.